US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

OpGen, Inc. - Common Stock (NQ:OPGN)

1.960 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OpGen, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Announces Acquisition of Preferred Stock by David Lazar
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
From OpGen, Inc.
Via GlobeNewswire
News headline image
Navigating the Roller Coaster of Recent Penny Stock Surges
Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks. 
Via MarketBeat
News headline image
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Announces Closing of $3.5 Million Public Offering
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Announces Pricing of $3.5 Million Public Offering
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics
From OpGen, Inc.
Via GlobeNewswire
News headline image
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Announces Exercise of All Prefunded Warrants
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen subsidiary Ares Genetics announces granting of key patent in China
From OpGen, Inc.
Via GlobeNewswire
News headline image
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
From OpGen, Inc.
Via GlobeNewswire
< Previous 1 2 Next >